Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis

Twenty-seven patients presenting within 5 days of the onset of crystalline proven acute gout were prospectively treated with either indomethacin 50 mg tid or triamcinolone acetonide 60 mg intramuscularly. Patients with contraindications to therapy with indomethacin received triamcinolone acetonide....

Full description

Saved in:
Bibliographic Details
Published inJournal of rheumatology Vol. 20; no. 1; p. 111
Main Authors Alloway, J A, Moriarty, M J, Hoogland, Y T, Nashel, D J
Format Journal Article
LanguageEnglish
Published Canada 01.01.1993
Subjects
Acute Disease
Administration, Oral
Adult
Aged
Arthritis, Gouty - drug therapy
Humans
Indomethacin - administration & dosage
Indomethacin - therapeutic use
Injections, Intramuscular
Male
Middle Aged
Prospective Studies
Treatment Outcome
Triamcinolone Acetonide - adverse effects
Triamcinolone Acetonide - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Twenty-seven patients presenting within 5 days of the onset of crystalline proven acute gout were prospectively treated with either indomethacin 50 mg tid or triamcinolone acetonide 60 mg intramuscularly. Patients with contraindications to therapy with indomethacin received triamcinolone acetonide. They were followed for 30 days. Resolution of all symptoms occurred at an average of 8 days for the indomethacin patients and 7 days in the triamcinolone patients. No side effects or episodes of rebound gout attacks occurred with the triamcinolone acetonide therapy. It is as safe and effective as indomethacin in the treatment of acute gout, and is particularly useful in patients with contraindications to therapy with nonsteroidal antiinflammatory drugs.
ISSN:0315-162X